Martina E, Damiani G, Grieco T, et al. - Since real‐life data focusing on patients > 65‐year‐old treated with omalizumab are rare, researchers conducted this retrospective study to test the safety and effectiveness of this biologic therapy in patients over 65 years of age. Sixty‐three patients, with a mean age of 72.3 ± 5.6 years, range: 65‐89) were recruited. No significant correlations between treatment effectiveness and comorbidities have been identified. In elderly patients with multiple comorbidities, omalizumab is also a safe and effective treatment.